… Editorial comment on: Low-activity V89L variant in SRD5A2 is associated with aggressive
prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials …

… Cholestenone 5 alpha-Reductase / antagonists & inhibitors* … Enzyme Inhibitors
Cholestenone 5 alpha-Reductase …

… By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.
… To arrive at the top five similar articles we use a word-weighted algorithm to compare words …

… The use of the 5-alpha reductase inhibitors (5-ARIs) … to act as a chemopreventive agent for
prostate cancer. The … , and nuclear SRD5A2 proteins using western blotting techniques [4]. …

… disease recurrence risk in Gleason score 7 prostate cancer. … For example, prostate cancer
Phase IB/II trials are ongoing … SRD5A2 transcript abundance has previously been reported …

… V89L variation in our patients was unknown. … Editorial comment on: Low-activity V89L variant
in SRD5A2 is … in chemoprevention trials using 5-alpha-reductase inhibitors. Eur Urol 2007;…

… It is explained with rs4149056, a variant present in SLCO1B1 … type 2 gene variant associations
with prostate cancer risk, … V89L polymorphisms in SRD5A2 gene may confer prostate …

… with oral squamous cell carcinoma at intermediate risk of recurrence treated by … advanced
nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials …